Data Integrity Inspections Go Global For Pharma
This article was originally published in SRA
Executive Summary
Data integrity inspections that have disrupted pharmaceutical exports from India to the US and Europe are spreading to exporters in China and other countries, as well as to domestic US and European manufacturers that may be unprepared for them.
You may also be interested in...
FDA Warning Letter Hits US Lab On Data Integrity, Password Sharing
Data integrity lapses raised in FDA warning letter to California analytical testing lab shows that such issues are not confined to Asia and that FDA will, in fact, challenge US facilities to show they are managing their quality data properly.
Remote Regulatory Assessments Will Continue Post Pandemic, Says US FDA
The US FDA has issued guidance on how it will continue to use remote technology to assess agency regulated facilities, a practice that became popular during COVID-19 travel restrictions.
US FDA Explains How It Is Embracing Remote Assessments Post-Pandemic
Agency provides additional details on plans for various remote methods of assessing Rx and OTC drug manufacturing facilities that became popular when investigators were prevented by COVID-19 travel restrictions from visiting sites in person.